Literature DB >> 22356664

The emerging buprenorphine epidemic in the United States.

Eric D Wish1, Erin Artigiani, Amy Billing, Wanda Hauser, Jordana Hemberg, Myron Shiplet, Robert L DuPont.   

Abstract

The authors sampled for expanded drug testing of 1,061 urine specimens collected by Maryland Division of Parole and Probation staff. They found an increase in the percentage of individuals testing positive for buprenorphine and found that these specimens often contained other drugs, suggesting misuse. Subsequent interviews with 15 probationers and parolees in Baltimore, Maryland, showed wide-scale availability of buprenorphine on the street and in prisons. Medical examiners and drug testing programs should immediately initiate routine testing for buprenorphine to track a possible outbreak of buprenorphine diversion and misuse. Physician education programs should redouble their efforts to teach strategies to deter diversion and misuse of the drug.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22356664     DOI: 10.1080/10550887.2011.642757

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  14 in total

1.  Expanding low-threshold buprenorphine to justice-involved individuals through mobile treatment: Addressing a critical care gap.

Authors:  Noa Krawczyk; Megan Buresh; Michael S Gordon; Thomas R Blue; Michael I Fingerhood; Deborah Agus
Journal:  J Subst Abuse Treat       Date:  2019-05-09

2.  Validity of Self-Reported Drug Use Information Among Pregnant Women.

Authors:  Mahek Garg; Laura Garrison; Lawrence Leeman; Ajna Hamidovic; Matthew Borrego; William F Rayburn; Ludmila Bakhireva
Journal:  Matern Child Health J       Date:  2016-01

3.  "Sub is a weird drug:" A web-based study of lay attitudes about use of buprenorphine to self-treat opioid withdrawal symptoms.

Authors:  Raminta Daniulaityte; Robert Carlson; Gregory Brigham; Delroy Cameron; Amit Sheth
Journal:  Am J Addict       Date:  2015-05-25

4.  Prenatally buprenorphine-exposed children: health to 3 years of age.

Authors:  Kaisa Kivistö; Sarimari Tupola; Satu Kivitie-Kallio
Journal:  Eur J Pediatr       Date:  2015-05-24       Impact factor: 3.183

5.  Buprenorphine treatment for narcotic addiction: not without risks.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Innov Clin Neurosci       Date:  2015 Mar-Apr

6.  Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.

Authors:  Todd Molfenter; Maureen Fitzgerald; Nora Jacobson; Dennis McCarty; Andrew Quanbeck; Mark Zehner
Journal:  J Psychoactive Drugs       Date:  2019-02-07

7.  Extended-release naltrexone for pre-release prisoners: A randomized trial of medical mobile treatment.

Authors:  Michael S Gordon; Frank J Vocci; Terrence T Fitzgerald; Kevin E O'Grady; Charles P O'Brien
Journal:  Contemp Clin Trials       Date:  2016-12-20       Impact factor: 2.226

8.  Self-management of buprenorphine/naloxone among online discussion board users.

Authors:  Shan-Estelle Brown; Frederick L Altice
Journal:  Subst Use Misuse       Date:  2014-06       Impact factor: 2.164

9.  Patterns of non-prescribed buprenorphine and other opioid use among individuals with opioid use disorder: A latent class analysis.

Authors:  Raminta Daniulaityte; Ramzi W Nahhas; Sydney Silverstein; Silvia Martins; Angela Zaragoza; Avery Moeller; Robert G Carlson
Journal:  Drug Alcohol Depend       Date:  2019-09-22       Impact factor: 4.492

10.  Consumer attitudes about opioid addiction treatment: a focus group study in New York City.

Authors:  Nancy L Sohler; Linda Weiss; James E Egan; Carolina M López; Jamie Favaro; Robert Cordero; Chinazo O Cunningham
Journal:  J Opioid Manag       Date:  2013 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.